Atlantic Coastal Acquisition Ii Stock Price, News & Analysis

ACABU represents units of Atlantic Coastal Acquisition Corp. II on the Nasdaq Global Market. According to public disclosures, Atlantic Coastal Acquisition Corp. II is a special purpose acquisition company (SPAC) formed to pursue a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Each ACABU unit initially consisted of one share of Series A common stock and one-half of one warrant, with each whole warrant exercisable to purchase one share of Series A common stock at a fixed exercise price.

In a later corporate development, Atlantic Coastal Acquisition Corp. II completed a business combination with Abpro Corporation. Following this transaction, the combined entity was renamed Abpro Holdings, Inc., and its common stock and warrants trade on the Nasdaq Stock Market under the symbols ABP and ABPWW, respectively. This means ACABU functions primarily as a historical trading symbol associated with the SPAC phase of the company before the completion of the business combination.

Abpro Holdings, Inc. is described in regulatory filings as an emerging growth company. It is associated with Abpro Corporation, a biotechnology company that focuses on next-generation antibody therapies for severe and life-threatening diseases. Abpro Corporation is located in Woburn, Massachusetts, and its mission is to improve the lives of patients through antibody-based treatments. After the business combination, Abpro Corporation became a wholly owned subsidiary of Abpro Holdings, Inc.

Corporate governance information for Abpro Holdings, Inc. is detailed in its proxy materials. The company has a classified board of directors divided into three classes with staggered terms. Matters such as director elections, ratification of the independent registered public accounting firm, and approval of a reverse stock split of common stock are presented to stockholders at annual meetings. These meetings are conducted virtually, and stockholders may vote electronically or by proxy.

The company’s proxy statement also outlines its board committees, corporate governance guidelines, code of business conduct, and policies regarding related party transactions and indemnification of directors and officers. Executive compensation, equity awards, and beneficial ownership information are described in detail for stockholders, reflecting the company’s status as a public registrant subject to U.S. Securities and Exchange Commission (SEC) reporting requirements.

From a historical perspective, investors researching ACABU are typically examining the SPAC stage of Atlantic Coastal Acquisition Corp. II and the path that led to the creation of Abpro Holdings, Inc. The business combination agreement, shareholder approvals, and subsequent listing of ABP and ABPWW on Nasdaq are key milestones in this transition from a blank check company to an operating biotechnology-focused public company.

Business combination and corporate evolution

According to SEC filings, on November 13, 2024, Atlantic Coastal Acquisition Corp. II completed a series of transactions that resulted in its combination with Abpro Corporation. A merger subsidiary of Atlantic Coastal merged with and into Abpro Corporation, with Abpro Corporation surviving as a wholly owned subsidiary. Immediately following the closing of this business combination, Atlantic Coastal Acquisition Corp. II changed its name to Abpro Holdings, Inc. This restructuring is central to understanding how the historical ACABU units relate to the current ABP and ABPWW securities.

The company’s later proxy materials refer to the combined entity as “New Abpro” and provide context on its governance, ownership, and capital structure after the business combination. Proposals such as a reverse stock split of common stock at a ratio of one-for-ten are presented to stockholders to manage the company’s share structure.

Regulatory status and exchange listing

Abpro Holdings, Inc. has securities registered under Section 12(b) of the Securities Exchange Act of 1934. Its common stock trades on the Nasdaq Stock Market under the symbol ABP, and its warrants trade under the symbol ABPWW. The company identifies itself as an emerging growth company under applicable SEC rules. These regulatory designations and exchange listings are important for investors tracking the evolution from ACABU units to the current equity and warrant securities.

Location and organizational details

Abpro Corporation is described as a biotechnology company located in Woburn, Massachusetts, with a mission to improve the lives of people facing severe and life-threatening diseases through next-generation antibody therapies. After the business combination, Abpro Holdings, Inc. is referenced in SEC filings with a principal office in Burlington, Massachusetts. These locations reflect the company’s presence in the biotechnology sector in the northeastern United States.

Use of proxy materials and stockholder rights

The company’s definitive proxy statement explains how stockholders can participate in annual meetings, vote on proposals, and access company documents such as the Annual Report on Form 10-K. It outlines the record date for determining stockholders entitled to vote, the number of shares outstanding on that date, and the procedures for voting by telephone, internet, or proxy card. The proxy materials also describe the absence of cumulative voting rights and the lack of appraisal or dissenters’ rights for the proposals presented.

ACABU as a historical symbol

For investors and researchers, ACABU primarily serves as a historical reference to the SPAC units of Atlantic Coastal Acquisition Corp. II. The subsequent business combination and renaming to Abpro Holdings, Inc., along with the listing of ABP and ABPWW, mean that current trading and corporate information is found under the Abpro Holdings, Inc. name and symbols. The ACABU overview is therefore most useful for understanding the origins of the public company structure that now supports Abpro’s biotechnology activities.